The U.S. FDA Priority Review Voucher Read more
Counterfeit, Substandard and Generic Drugs: Distinct Definitions for Distinctly Different Problems Read more
Valganciclovir Patent Set Aside in India read MSF's statement
New MSF report shows Europe failing to pay fair share of TB research
MSF hosts malnutrition symposium in NY Read more
|
 |
|
 |
|
 |
Medical Innovation
|
Cough Up for TB ! MSF publishes new report revealing how Europe is failing to match up to the funding needs for new medical tools to beat tuberculosis Read more Press Release: Europe Failing to Respond to Global TB Threat
|
|
|
Taking the Plunge: MSF welcomes UNITAID's decision to give the go-ahead for the creation of a 'patent pool' This innovative mechanism could help the development of much needed new medicines at affordable prices Read more
|
|
GAVI Plan is Flawed: Donors have held their final meeting in Canada to conclude a deal on the pilot Advance Market Commitment for the pneumococcal vaccine. The vaccine could save millions of lives. But GAVI's current proposal is too expensive. MSF is urging donors to think before they leap Read more
|
|
|
Championing open source drugs: Leading geneticist Samir Brahmachari explains why India should kickstart a new 'open source' approach to drug discovery for diseases like TB. |
Major step forward WHO agrees on a plan to reform the medical R&D system and enhance access to medicines for patients in developing countries MSF statement Listen to the podcast on outcome of WHA and why it matters to our patients
|
Give us the tools we need...From an effective diagnostic test for TB, to drugs that work against Chagas disease and HIV treatments for children and pregnant women - none of these are available to our teams in the field because of the failure of the current system of medical R&D. Click here to read more about the medical challenges we face and some solutions that might deliver the medical tools we need to treat our patients. |
New Trials for Drug-Resistant TB
In a series of papers published by PLoS, international experts explain how innovative trials in patients with drug resistant TB could speed up delivery of new drugs, explore how to fill up the current TB pipeline with additional promising drugs and call for building of clinical trial capacity in developing countries. Paper on Randomized drug trials |
Introduction to Medical Innovation
Looking for alternative models
|
